2 Growth Stocks That Can Double Your Portfolio In 2022

Here's why growth stocks such as Teladoc Health and Lightspeed Commerce should be on the shopping list of investors at current valuations.
Jan. 27, 2022
Unlock Free Stock Insights + 50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

Major equity indices have lost momentum in the last few trading sessions as investors are worried about steep valuations surrounding growth stocks and the possibility of multiple interest rate hikes in 2022. However, the ongoing pullback provides investors an opportunity to buy quality stocks at a cheaper valuation.

Here, we take a look at two such growth stocks that can double your investment in the next year, according to Wall Street estimates.

Teladoc Health

Teladoc (NYSE: TDOC) is a health-tech company valued at a market cap of $11.1 billion. The COVID-19 pandemic acted as a massive tailwind for Teladoc and peers as demand for virtual health services increased rapidly due to social distancing measures. As a result, Teladoc increased sales by 96% year over year to $1.09 billion in 2020.

However, the company also increased revenue at an annual rate of 74% in the seven years prior to 2020. In addition, Teladoc closed the acquisition of Livongo Health for $18.5 billion, ensuring it ends 2021 with revenue of $2 billion, up 80% year over year.

Despite its enticing top-line growth, TDOC stock is down 76% from all-time highs as its revenue growth is forecast to decelerate to 27% in fiscal 2022. Teladoc is valued at a forward price to 2022 sales multiple of less than 6x, which is quite reasonable. While unprofitable, the company is also poised to narrow loss per share from $5.36 in 2020 to $1.65 per share in 2022.

A report from Markets and Markets estimates the global telehealth market to touch $191.7 billion in 2025, up from $38.7 billion in 2020, giving Teladoc enough room to grow organically in the upcoming decade.

Analysts have a 12-month average price target of $144 for TDOC stock which is 107% above its current trading price.

Lightspeed Commerce

A Canada-based fintech company, Lightspeed Commerce (NYSE: LSPD), is down 77% from record highs, valuing it at a market cap of $4.31 billion. Lightspeed shares were decimated in Q4 of 2021 after a short-seller report published by Spruce Point Capital accused the company of misleading investors and claimed that an aggressive acquisition strategy drove revenue growth.

However, Lightspeed has increased sales from $57 million in fiscal 2018 ended in March, to $221.7 million in fiscal 2021. It now expects revenue between $520 million and $535 million in fiscal 2022, valuing LSPD stock at a forward price to sales multiple of 8.11x.

Lightspeed derives its revenue by selling point-of-sale devices to small and medium enterprises. It ended the September quarter with a customer base of 156,000, up from 49,000 in fiscal 2019. Further, LSPD's average revenue per customer rose to $270 in fiscal Q2 of 2022, compared to $170 in the year-ago period.

Similar to Teladoc, Lightspeed is also unprofitable but is forecast to report a loss per share of $0.21 in fiscal 2023, compared to a loss of $1.16 per share in fiscal 2021. Analysts tracking LSPD stock expect it to rise to $84 in the next 12-months, almost 200% above its current trading price.


Unlock Free Stock Insights +50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.


Services

Content

Social

Company

Support

Resources


This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.